OTCM
HBRM
Market cap962kUSD
Jul 10, Last price
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
0.00%
Name
Herborium Group Inc
Chart & Performance
Profile
Herborium Group, Inc., a botanical therapeutics company, develops, licenses, and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. It offers dermatology products, which include AcnEase, herbal medicinal product for enhancing conditions associated with hormonal acne and multiple symptoms of Rosacea; and AcnEase Skin Management System for the treatment of acne marks/scars. The company also provides sexual health and performance products that are non-prescriptive alternatives to selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, and surgical procedures, including hysterectomy. In addition, it offers energy restoration products, such as Lasting Energy, a herbal supplement to decrease the symptoms associated with hangovers and eliminating jet-lag; and for treating overall depletion of energy due to competitive sports, high levels of stress, and extensive sexual activities, as well as other long term or temporary physical demands. Further, the company provides Liver Activator Series for the treatment of liver damage; ProstAid, a natural product focuses on Benign Prostate Hyperplasia; and CardioVitae, a fermentation based product using a Lucidium derived cell line targeting cardio-pulmonary insufficiencies. Herborium Group, Inc. sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. The company was founded in 2000 and is headquartered in Fort Lee, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
Income | ||||||||
Revenues | 1,119 -1.21% | 1,133 7.81% | ||||||
Cost of revenue | 531 | 462 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 589 | 671 | ||||||
NOPBT Margin | 52.59% | 59.24% | ||||||
Operating Taxes | (168) | |||||||
Tax Rate | ||||||||
NOPAT | 757 | 671 | ||||||
Net income | 30 -111.06% | (267) -18.78% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
Debt | ||||||||
Debt current | 402 | 402 | ||||||
Long-term debt | 668 | 650 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | (1) | |||||||
Net debt | 1,059 | 1,038 | ||||||
Cash flow | ||||||||
Cash from operating activities | 370 | (133) | ||||||
CAPEX | (2) | (2) | ||||||
Cash from investing activities | (2) | (2) | ||||||
Cash from financing activities | (371) | 145 | ||||||
FCF | 1,100 | 795 | ||||||
Balance | ||||||||
Cash | 10 | 14 | ||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | (15,040) | (15,041) | ||||||
Invested Capital | 11,793 | 12,137 | ||||||
ROIC | 6.32% | 9.22% | ||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 10,737,131 | 9,686,973 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 589 | 676 | ||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT |